Microbiology Devices; Classification of In Vitro Diagnostic Devices for Bacillus Species Detection
fda-device · Food and Drug Administration · Rule · Published 2019-04-01 · Effective 2019-05-01 · 84 FR 12083
Document
Document number
2019-06026
Federal Register citation
84 FR 12083
CFR reference
21 CFR 866
Type
Rule
Action
Final rule.
Category
fda-device
Sub-agency
Food and Drug Administration
Publication date
2019-04-01
Effective date
2019-05-01
HHS docket
Docket No. FDA-2011-N-0103
Abstract
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to classify in vitro diagnostic devices for Bacillus species (spp.) detection into class II (special controls) and to continue to require a premarket notification (510(k)) to provide a reasonable assurance of safety and effectiveness of the device. FDA is also establishing special controls in a special controls guideline in addition to restricting use and distribution of the devices. An in vitro diagnostic device for Bacillus spp. detection is a prescription device used to detect and differentiate among Bacillus spp. and presumptively identify B. anthracis and other Bacillus spp. from cultured isolates or clinical specimens as an aid in the diagnosis of anthrax and other diseases caused by Bacillus spp.